NCT05382364View on ClinicalTrials.gov

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Metastatic HER2+ Advanced Breast CancerBreast NeoplasmsGastric or Gastroesophageal Junction Adenocarcinoma (GEC)Colorectal Cancer
Interventions
DRUG

Tucatinib

Tucatinib 150 mg and 50 mg tablets taken by mouth at a dose of 300 mg twice daily.

Trial Locations (5)

130012

Jilin Cancer Hospital, Changchun

150081

Harbin Medical University Cancer Hospital, Harbin

200032

Fudan University Shanghai Cancer Center, Shanghai

421000

Hunan Cancer Hospital, Changsha

Unknown

Tianjin Medical University Cancer Institute and Hospital, Tianjin

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY